RT Journal Article
SR Electronic
T1 Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e003831
DO 10.1136/jitc-2021-003831
VO 10
IS 1
A1 Xia, Lingfang
A1 Peng, Jin
A1 Lou, Ge
A1 Pan, Mei
A1 Zhou, Qi
A1 Hu, Wenjing
A1 Shi, Huirong
A1 Wang, Li
A1 Gao, Yunong
A1 Zhu, Jianqing
A1 Zhang, Yu
A1 Sun, Rong
A1 Zhou, Xianfeng
A1 Wang, Quanren
A1 Wu, Xiaohua
YR 2022
UL http://jitc.bmj.com/content/10/1/e003831.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.